DOCSLIB.ORG

Antimicrobial Prescribing Quick Reference Guide for Primary Care in Nottinghamshire

Total Page：16

File Type：pdf, Size：1020Kb

Download full-text PDF Read full-text
Antimicrobial Prescribing Quick Reference Guide for Primary Care in Nottinghamshire Antimicrobial Prescribing Quick Reference Guide for Primary Care in Nottinghamshire For further information and management of other infections not listed here please refer to the full guideline on the Area Prescribing Committee website: http://www.nottsapc.nhs.uk Where empirical therapy has failed or special circumstances (e.g. previous C.difficile infection) exist, clinical advice should be sought from Microbiology Department at either Nottingham University Hospitals 01159249924 ext 61163 or Sherwood Forest Hospitals 01623622515 ext 3616 Infection Notes Recommended Agent(s) Doses are for adults unless otherwise stated Upper Respiratory Tract Infections Consider a delayed prescription (3-5 days) Pharyngitis / as the majority are viral Phenoxymethylpenicillin 1g BD for 10 days Tonsillitis (or 500mg - 1g QDS if severe) 90% resolve in 7 days without antibiotics NICE CG69 Consider immediate or a 3 day delayed Penicillin allergy: prescription if Centor score of 3 or 4: Clarithromycin 250-500mg BD for 5 days CKS Lymphadenopathy, No cough, Fever, (consider Erythromycin syrup in children) Tonsillar Exudate Amoxicillin for 5 days Consider no or delayed prescribing if not Neonate 7-28 days: 30mg/kg TDS, acutely unwell; illness resolves over 4 days 1month-1 yr: 125mg TDS, 1-5yrs: 250mg TDS, >5yrs and adults: 500mg TDS Acute Otitis Media in 80% without antibiotics. If acutely unwell (vomiting, fever, pain for Penicillin allergy: CKS >48h and otorrhoea) prescribe immediate Clarithromycin 250-500mg BD for 5 days antibiotics. Consider Erythromycin syrup in children: 1month-2yrs: 125mg QDS; 2-8yrs: 250mg QDS; >8yrs: 500mg QDS for 5 days First line: Organisms usually present as secondary Acetic acid 2% TDS (EarCalm Spray) for 7 days colonisers Otitis Externa Cure rates similar at 7 days for acetic acid Second line options: or antibiotic +/- steroid Gentisone HC, Locorten-Vioform, Sofradex CKS Oral antibiotics only indicated if spreading cellulitis If spreading cellulitis: Flucloxacillin 500mg QDS for 5 days Majority are viral and resolve in 7-10 days Treat for 7 days: without antibiotics Acute Sinusitis Phenoxymethylpenicillin 500mg QDS Reserve antibiotics for severe or or symptoms >10 days Amoxicillin 500mg TDS (1g TDS if severe) CKS In persistent infection despite first line or therapy, use co-amoxiclav. Doxycycline 200mg stat then 100mg OD Lower Respiratory Tract Infections Numerous RCTs have shown little or no Doxycycline 200mg stat then 100mg OD for benefit of antibiotics in otherwise healthy Acute Cough, 5 days adults Bronchitis Consider antibiotics if >80yrs and one of or the following: hospitalisation in past year, CKS oral steroids, diabetic, heart failure. Or if Amoxicillin 500mg TDS for 5 days >65yrs and two of the above. Doxycycline 200mg stat then 100mg OD Acute Antibiotics are helpful when purulent or Exacerbation of sputum and increased shortness of breath Amoxicillin 500mg TDS COPD and/or increased sputum volume. or Consider risk factors for resistant Clarithromycin 500mg BD for 5 days CKS organisms: frequent exacerbations, severe COPD, comorbid disease, antibiotics in If resistance likely: NICE CG12 last 3 months. Co-amoxiclav 625mg TDS for 5 days Use CRB65 score to guide management: CRB65 = 0: Amoxicillin 500mg TDS or Confusion (new AMT <8) Doxycycline 200mg stat / 100mg OD or Community Respiratory rate >30 breaths/minute Clarithromycin 500mg BD for 5 days Acquired BP systolic <90 or diastolic <60 Pneumonia Age >65 years CRB65 = 1 and at home: Doxycycline 200mg stat / 100mg OD for 7-10 BTS 2009 0= suitable for home treatment days or 1-2 = hospital assessment or admission Amoxicillin 500mg-1g TDS plus 3-4 = urgent hospital admission Clarithromycin 500mg BD for 7-10 days Authors: Dr Amelia Joseph, Specialty Registrar and Dr Fiona Donald, Consultant in Microbiology, Nottingham University Hospitals NHS Trust; James Sutton, Formulary Pharmacist, Mansfield and Ashfield CCG. Updated May 2015. Review date: May 2018. Genital Tract Infections Vaginal All topical and oral azoles give 75% cure. Clotrimazole 500mg pessary or Candidiasis 10% vaginal cream 5g single application CKS In pregnancy avoid oral azoles and use or BASHH intravaginal treatment for 7 days. Fluconazole 150mg orally single dose Opportunistically screen 16-25yr olds. Azithromycin 1g single dose or Refer to GUM for contact tracing and full Chlamydia Doxycycline 100mg BD 7 days sexual health screen. trachomatis Pregnancy or breastfeeding: Azithromycin Pregnancy or breastfeeding: BASHH is the most effective option (unlicensed). Azithromycin (off-label) 1g single dose Lower cure rate in pregnancy, test for cure or Erythromycin 500mg QDS for 7 days at 6 weeks. or Amoxicillin 500mg TDS for 7 days Refer to GUM for management, contact tracing and full sexual health screen. If Neisseria patient unwilling or cannot access within a Ceftriaxone 500mg IM injection gonorrhoeae reasonable time, then treatment for plus uncomplicated gonorrhoea can be initiated Azithromycin 1g PO single dose BASHH on basis of a positive Microbiology result. Cefixime is no longer recommended. Test of cure at 2-4 weeks recommended. Send pre-treatment MSU and review with Acute Prostatitis Treat for 28 days: results. First line: Ciprofloxacin 500mg BD Quinolones more effective but risk of CKS Second line: Trimethoprim 200mg BD adverse events e.g. C.difficile. Send cervical swab for MC&S for Pelvic Ceftriaxone 500mg IM stat N.gonorrhoeae, and cervical swab for Inflammatory plus NAATs for C.trachomatis +/- N.gonorrhoeae Disease Metronidazole 400mg BD for 14 days Consider referral to GUM plus Suspected PID in pregnancy requires urgent BASHH Doxycycline 100mg BD for 14 days hospital assessment Gastrointestinal Infections Treat positives in known DU, GU or low- First line: grade MALToma. Lansoprazole 30mg BD plus Do not offer eradication in GORD. Amoxicillin 1g BD plus Eradication of Treatment duration is 7 days for DU / GU Either Clarithromycin 500mg BD or H.pylori and 14 days for MALToma. Metronidazole 400mg BD Do not use clarithromycin or metronidazole NICE CG184 if used in the past year for another Penicillin allergy: indication. Lansoprazole 30mg BD plus Clarithromycin 500mg BD plus See full guideline for second line therapy and Metronidazole 400mg BD treatment failures. Stop unnecessary antibiotics and PPIs. Mild disease: Clostridium Avoid anti-motility drugs in Metronidazole 400mg TDS for 10-14 days difficile diarrhoea suspected/confirmed disease. For severe or recurrent disease see full PHE C.difficile Assess severity (see full guideline) and consider admission if severe. guideline. Treat household contacts concurrently. Mebendazole in >6 months: Threadworms Hygiene advice: morning baths/showers, 100mg single dose (not in pregnancy) hand-washing, nail cutting, wash bed linen. Piperazine/senna sachet 3-6 months: CKS Mebendazole contraindicated in pregnancy 2.5ml stirred into water, repeat after 2 wks and in <6 months of age. Routine use of antibiotics in uncomplicated Co-amoxiclav 625mg TDS for 7 days Acute diverticulitis is to be avoided. Diverticulitis Penicillin allergy: Restrict prescribing to patients with signs of systemic infection and review within 48 Ciprofloxacin 500 mg BD plus CKS hours to assess clinical response. Metronidazole 400mg TDS for 7 days Skin and Soft Tissue Infections Topical therapy should be reserved for First line: only very minor infections to minimise Flucloxacillin resistance. 1mnth-2yrs: 125mg QDS The topical agent of choice is: 2-10yrs: 250mg QDS Impetigo Polyfax Ointment applied BD for 5 days. >10yrs and adult: 500mg QDS Topical fusidic acid should be avoided due to resistance rates, which may lead to Clarithromycin for 7 days: treatment failures. >12yrs and adults: 250-500mg BD In children consider Erythromycin syrup: 1mnth-2yrs: 125mg QDS Oral therapy is advised in all but very minor 2-8yrs: 250mg QDS infections. Child >8yrs: 500mg QDS If there is evidence of systemic infection, rapidly spreading cellulitis or severe pain Treat for 7-14 days until clinical response. urgent hospital referral is required. First line: In facial cellulitis, use Co-amoxiclav 625mg Cellulitis Flucloxacillin 500mg QDS TDS instead to extend cover to respiratory pathogens. CKS Penicillin allergy: In South Nottinghamshire there is a Clarithromycin 500mg BD community based IV antibiotics service for In children consider Erythromycin syrup. uncomplicated cellulitis as an alternative to hospital admission, contact 0115 846 2376 Leg ulcers In the absence of cellulitis, treatment not indicated. Send swabs only if clinical evidence of PHE infection. Consider referral to Tissue Viability if difficult cases. Antibiotics should only be used when First line: Diabetic foot surrounding cellulitis present. Co-amoxiclav 625mg TDS for 7-14 days infections Refer to hospital if ulcer rapidly Penicillin allergy: deteriorating or systemically unwell. Clindamycin 300mg QDS for 7-14 days Refer to full guideline for information on Human or Animal prophylaxis and treatment on bite wounds. First line: Bites When Co-amoxiclav is unsuitable and in Co-amoxiclav 625mg TDS for 7 days CKS penicillin allergy, refer to the full guideline. Most are self-limiting, 64% self-resolve. If severe: Chloramphenicol 0.5% drops Bacterial Consider delayed prescribing strategy 4-5 2 hourly for 48 hours, then 4 hourly. Conjunctivitis days for mild cases. Treat if severe or Chloramphenicol 1% eye ointment TDS infection. CKS PHE recommend not normally necessary Continue for 48 hours after resolution.
Load more

Recommended publications
  • Efficacy of Amoxicillin and Amoxicillin/Clavulanic Acid in the Prevention of Infection and Dry Socket After Third Molar Extraction
    Med Oral Patol Oral Cir Bucal. 2016 Jul 1;21 (4):e494-504. Amoxicillin in the prevention of infectious complications after tooth extraction Journal section: Oral Surgery doi:10.4317/medoral.21139 Publication Types: Review http://dx.doi.org/doi:10.4317/medoral.21139 Efficacy of amoxicillin and amoxicillin/clavulanic acid in the prevention of infection and dry socket after third molar extraction. A systematic review and meta-analysis María-Iciar Arteagoitia 1, Luis Barbier 2, Joseba Santamaría 3, Gorka Santamaría 4, Eva Ramos 5 1 MD, DDS, PhD, Associate Professor, Stomatology I Department, University of the Basque Country (UPV/EHU), BioCruces Health Research Institute, Spain; Consolidated research group (UPV/EHU IT821-13) 2 MD PhD, Chair Professor, Maxillofacial Surgery Department, BioCruces Health Research Institute, Cruces University Hos- pital, University of the Basque Country (UPV/EHU), Spain; Consolidated research group (UPV/EHU IT821-13) 3 MD, DDS, PhD, Professor and Chair, Maxillofacial Surgery Department, Bio Cruces Health Research Institute, Cruces University Hospital, University of the Basque Country (UPV/EHU), Bizkaia, Spain; Consolidated research group (UPV/EHU IT821-13) 4 DDS, PhD, Associate Professor, Stomatology I Department, University of the Basque Country (UPV/EHU), BioCruces Health Research Institute, Spain; Consolidated research group (UPV/EHU IT821-13) 5 PhD, Degree in Farmacy, BioCruces Health Research Institute, Cruces University Hospital. Spain Correspondence: Servicio Cirugía Maxilofacial Hospital Universitario de Cruces Plaza de Cruces s/n Arteagoitia MI, Barbier L, Santamaría J, Santamaría G, Ramos E. Ef- Barakaldo, Bizkaia, Spain ficacy of amoxicillin and amoxicillin/clavulanic acid in the prevention [email protected] of infection and dry socket after third molar extraction.
    [Show full text]
  • Cefalexin in the WHO Essential Medicines List for Children Reject
    Reviewer No. 1: checklist for application of: Cefalexin In the WHO Essential Medicines List for Children (1) Have all important studies that you are aware of been included? Yes No 9 (2) Is there adequate evidence of efficacy for the proposed use? Yes 9 No (3) Is there evidence of efficacy in diverse settings and/or populations? Yes 9 No (4) Are there adverse effects of concern? Yes 9 No (5) Are there special requirements or training needed for safe/effective use? Yes No 9 (6) Is this product needed to meet the majority health needs of the population? Yes No 9 (7) Is the proposed dosage form registered by a stringent regulatory authority? Yes 9 No (8) What action do you propose for the Committee to take? Reject the application for inclusion of the following presentations of cefalexin: • Tablets/ capsules 250mg • Oral suspensions 125mg/5ml and 125mg/ml (9) Additional comment, if any. In order to identify any additional literature, the following broad and sensitive search was conducted using the PubMed Clinical Query application: (cephalexin OR cefalexin AND - 1 - pediatr*) AND ((clinical[Title/Abstract] AND trial[Title/Abstract]) OR clinical trials[MeSH Terms] OR clinical trial[Publication Type] OR random*[Title/Abstract] OR random allocation[MeSH Terms] OR therapeutic use[MeSH Subheading]) Only one small additional study was identified, which looked at the provision of prophylactic antibiotics in patients presenting to an urban children's hospital with trauma to the distal fingertip, requiring repair.1 In a prospective randomised control trial, 146 patients were enrolled, of which 69 were randomised to the no-antibiotic group, and 66 were randomised to the antibiotic (cefalexin) group.
    [Show full text]
  • Medicines to Treat Bacterial Infections
    Government of Western Australia North Metropolitan Health Service Women and Newborn Health Service Medicines to treat bacterial infections This brochure contains some information on Important: Antibiotic resistance can the medicines you may have been prescribed affect us all. to treat a bacterial infection either in hospital or on discharge. Please talk to your doctor or Help limit the development of antibiotic pharmacist if you would like more information resistance by using antibiotics correctly. on a specific antibiotic. Make sure you: Take antibiotics exactly as prescribed. What is an antibiotic? • Antibiotics are medicines used to treat • Follow instructions on how many times a infections caused by bacteria. They are not day and for how long to take them. effective against viral infections such as the • Do not stop treatment early, even if you common cold and the ‘flu’. feel better. Medicine Other information Amoxicillin May be taken with or without food. Amoxicillin/ Take with the first bite of a meal. clavulanic acid Cefalexin May be taken with or without food. Take on an empty stomach with a glass of water, 1 hour before or 2 hours after food. Ciprofloxacin Do not take dairy products, antacids, iron, zinc or calcium within 2 hours of the dose. Clindamycin Take with a full glass of water. May be taken with or without food. Take with food or milk. Remain upright for an hour after dose to prevent damage to the Doxycycline lining of your throat. Do not take dairy products, antacids, iron, zinc or calcium within 2 hours of the dose. Take on an empty stomach, 1 hour before or 2 hours after food.
    [Show full text]
  • Antimicrobial Resistance Benchmark 2020 Antimicrobial Resistance Benchmark 2020
    First independent framework for assessing pharmaceutical company action Antimicrobial Resistance Benchmark 2020 Antimicrobial Resistance Benchmark 2020 ACKNOWLEDGEMENTS The Access to Medicine Foundation would like to thank the following people and organisations for their contributions to this report.1 FUNDERS The Antimicrobial Resistance Benchmark research programme is made possible with financial support from UK AID and the Dutch Ministry of Health, Welfare and Sport. Expert Review Committee Research Team Reviewers Hans Hogerzeil - Chair Gabrielle Breugelmans Christine Årdal Gregory Frank Fatema Rafiqi Karen Gallant Nina Grundmann Adrián Alonso Ruiz Hans Hogerzeil Magdalena Kettis Ruth Baron Hitesh Hurkchand Joakim Larsson Dulce Calçada Joakim Larsson Marc Mendelson Moska Hellamand Marc Mendelson Margareth Ndomondo-Sigonda Kevin Outterson Katarina Nedog Sarah Paulin (Observer) Editorial Team Andrew Singer Anna Massey Deirdre Cogan ACCESS TO MEDICINE FOUNDATION Rachel Jones The Access to Medicine Foundation is an independent Emma Ross non-profit organisation based in the Netherlands. It aims to advance access to medicine in low- and middle-income Additional contributors countries by stimulating and guiding the pharmaceutical Thomas Collin-Lefebvre industry to play a greater role in improving access to Alex Kong medicine. Nestor Papanikolaou Address Contact Naritaweg 227-A For more information about this publication, please contact 1043 CB, Amsterdam Jayasree K. Iyer, Executive Director The Netherlands [email protected] +31 (0) 20 215 35 35 www.amrbenchmark.org 1 This acknowledgement is not intended to imply that the individuals and institutions referred to above endorse About the cover: Young woman from the Antimicrobial Resistance Benchmark methodology, Brazil, where 40%-60% of infections are analyses or results.
    [Show full text]
  • Antibiotic Use Guidelines for Companion Animal Practice (2Nd Edition) Iii
    ii Antibiotic Use Guidelines for Companion Animal Practice (2nd edition) iii Antibiotic Use Guidelines for Companion Animal Practice, 2nd edition Publisher: Companion Animal Group, Danish Veterinary Association, Peter Bangs Vej 30, 2000 Frederiksberg Authors of the guidelines: Lisbeth Rem Jessen (University of Copenhagen) Peter Damborg (University of Copenhagen) Anette Spohr (Evidensia Faxe Animal Hospital) Sandra Goericke-Pesch (University of Veterinary Medicine, Hannover) Rebecca Langhorn (University of Copenhagen) Geoffrey Houser (University of Copenhagen) Jakob Willesen (University of Copenhagen) Mette Schjærff (University of Copenhagen) Thomas Eriksen (University of Copenhagen) Tina Møller Sørensen (University of Copenhagen) Vibeke Frøkjær Jensen (DTU-VET) Flemming Obling (Greve) Luca Guardabassi (University of Copenhagen) Reproduction of extracts from these guidelines is only permitted in accordance with the agreement between the Ministry of Education and Copy-Dan. Danish copyright law restricts all other use without written permission of the publisher. Exception is granted for short excerpts for review purposes. iv Foreword The first edition of the Antibiotic Use Guidelines for Companion Animal Practice was published in autumn of 2012. The aim of the guidelines was to prevent increased antibiotic resistance. A questionnaire circulated to Danish veterinarians in 2015 (Jessen et al., DVT 10, 2016) indicated that the guidelines were well received, and particularly that active users had followed the recommendations. Despite a positive reception and the results of this survey, the actual quantity of antibiotics used is probably a better indicator of the effect of the first guidelines. Chapter two of these updated guidelines therefore details the pattern of developments in antibiotic use, as reported in DANMAP 2016 (www.danmap.org).
    [Show full text]
  • Summary of Product Characteristics
    SUMMARY OF PRODUCT CHARACTERISTICS 1 1. NAME OF THE MEDICINAL PRODUCT Augmentin 125 mg/31.25 mg/5 ml powder for oral suspension Augmentin 250 mg/62.5 mg/5 ml powder for oral suspension 2. QUALITATIVE AND QUANTITATIVE COMPOSITION When reconstituted, every ml of oral suspension contains amoxicillin trihydrate equivalent to 25 mg amoxicillin and potassium clavulanate equivalent to 6.25 mg of clavulanic acid. Excipients with known effect Every ml of oral suspension contains 2.5 mg aspartame (E951). The flavouring in Augmentin contains maltodextrin (glucose) (see section 4.4). This medicine contains less than 1 mmol sodium (23 mg) per ml, that is to say essentially ‘sodium- free’. When reconstituted, every ml of oral suspension contains amoxicillin trihydrate equivalent to 50 mg amoxicillin and potassium clavulanate equivalent to 12.5 mg of clavulanic acid. Excipients with known effect Every ml of oral suspension contains 2.5 mg aspartame (E951). The flavouring in Augmentin contains maltodextrin (glucose) (see section 4.4). This medicine contains less than 1 mmol sodium (23 mg) per ml, that is to say essentially ‘sodium- free’. For the full list of excipients, see section 6.1. 3. PHARMACEUTICAL FORM Powder for oral suspension. Off-white powder. 4. CLINICAL PARTICULARS 4.1 Therapeutic indications Augmentin is indicated for the treatment of the following infections in adults and children (see sections 4.2, 4.4 and 5.1): • Acute bacterial sinusitis (adequately diagnosed) • Acute otitis media • Acute exacerbations of chronic bronchitis (adequately diagnosed) • Community acquired pneumonia • Cystitis • Pyelonephritis 2 • Skin and soft tissue infections in particular cellulitis, animal bites, severe dental abscess with spreading cellulitis • Bone and joint infections, in particular osteomyelitis.
    [Show full text]
  • Ceftaroline in the Management of Complicated Skin and Soft Tissue Infections and Community Acquired Pneumonia
    Journal name: Therapeutics and Clinical Risk Management Article Designation: Review Year: 2015 Volume: 11 Therapeutics and Clinical Risk Management Dovepress Running head verso: Mpenge and MacGowan Running head recto: Ceftaroline in the management of cSSTI and CAP open access to scientific and medical research DOI: http://dx.doi.org/10.2147/TCRM.S75412 Open Access Full Text Article REVIEW Ceftaroline in the management of complicated skin and soft tissue infections and community acquired pneumonia Mbiye A Mpenge¹ Abstract: Ceftaroline is a new parenteral cephalosporin approved by the European Medicines Alasdair P MacGowan² Agency (EMA) and the US Food and Drug Administration (FDA) for the treatment of com- plicated skin and soft tissue infections (cSSTIs) including those due to methicillin-resistant ¹Department of Medical Microbiology, University Hospitals Bristol NHS Staphylococcus aureus (MRSA), and community-acquired pneumonia (CAP). Ceftaroline has Trust, Bristol Royal Infirmary, Bristol, broad-spectrum activity against gram-positive and gram-negative bacteria and exerts its bacteri- England; ²Department of Medical Microbiology, North Bristol NHS cidal effects by binding to penicillin-binding proteins (PBPs), resulting in inhibition of bacterial Trust, Southmead Hospital, Bristol, cell wall synthesis. It binds to PBP 2a of MRSA with high affinity and also binds to all six PBPs England in Streptococcus pneumoniae. In in vitro studies, ceftaroline demonstrated potent activity against Staphylococcus aureus (including MRSA and vancomycin-intermediate isolates), Streptococ- For personal use only. cus pneumoniae (including multidrug resistant isolates), Haemophilus influenzae, Moraxella catarrhalis, and many common gram-negative pathogens, excluding extended spectrum beta- lactamase (ESBL)-producing Enterobacteriaceae and Pseudomonas aeruginosa. In Phase II and Phase III clinical trials, ceftaroline was noninferior to its comparator agents and demonstrated high clinical cure rates in the treatment of cSSTIs and CAP.
    [Show full text]
  • AMEG Categorisation of Antibiotics
    12 December 2019 EMA/CVMP/CHMP/682198/2017 Committee for Medicinal Products for Veterinary use (CVMP) Committee for Medicinal Products for Human Use (CHMP) Categorisation of antibiotics in the European Union Answer to the request from the European Commission for updating the scientific advice on the impact on public health and animal health of the use of antibiotics in animals Agreed by the Antimicrobial Advice ad hoc Expert Group (AMEG) 29 October 2018 Adopted by the CVMP for release for consultation 24 January 2019 Adopted by the CHMP for release for consultation 31 January 2019 Start of public consultation 5 February 2019 End of consultation (deadline for comments) 30 April 2019 Agreed by the Antimicrobial Advice ad hoc Expert Group (AMEG) 19 November 2019 Adopted by the CVMP 5 December 2019 Adopted by the CHMP 12 December 2019 Official address Domenico Scarlattilaan 6 ● 1083 HS Amsterdam ● The Netherlands Address for visits and deliveries Refer to www.ema.europa.eu/how-to-find-us Send us a question Go to www.ema.europa.eu/contact Telephone +31 (0)88 781 6000 An agency of the European Union © European Medicines Agency, 2020. Reproduction is authorised provided the source is acknowledged. Categorisation of antibiotics in the European Union Table of Contents 1. Summary assessment and recommendations .......................................... 3 2. Introduction ............................................................................................ 7 2.1. Background ........................................................................................................
    [Show full text]
  • Eml-2017-Antibacterials-Eng.Pdf
    Consideration of antibacterial medicines as part of the revisions to 2017 WHO Model List of Essential Medicines for adults (EML) and Model List of Essential Medicines for children (EMLc) Section 6.2 Antibacterials including Access, Watch and Reserve Lists of antibiotics This summary has been prepared by the Health Technologies and Pharmaceuticals (HTP) programme at the WHO Regional Office for Europe. It is intended to communicate changes to the 2017 WHO Model List of Essential Medicines for adults (EML) and Model List of Essential Medicines for children (EMLc) to national counterparts involved in the evidence-based selection of medicines for inclusion in national essential medicines lists (NEMLs), lists of medicines for inclusion in reimbursement programs, and medicine formularies for use in primary, secondary and tertiary care. This document does not replace the full report of the WHO Expert Committee, 2017 and this summary should be read in conjunction with the full report (WHO Technical Report Series, No. 1006; http://apps.who.int/iris/bitstream/10665/259481/1/9789241210157-eng.pdf?ua=1). The revised lists of essential medicines (in English) are available as follows: 2017 WHO Model List of Essential Medicines for adults (EML) http://www.who.int/medicines/publications/essentialmedicines/20th_EML2017_FINAL_amend edAug2017.pdf?ua=1 2017 Model List of Essential Medicines for children (EMLc) http://www.who.int/medicines/publications/essentialmedicines/6th_EMLc2017_FINAL_amend edAug2017.pdf?ua=1 Summary of changes to Section 6.2 Antibacterials: Section 6 of the EML covers anti-infective medicines. Disease-specific subsections within Section 6, such as those covering medicines for tuberculosis, HIV, hepatitis and malaria, have been regularly reviewed and updated, taking into consideration relevant WHO treatment guidelines.
    [Show full text]
  • Computational Antibiotics Book
    Andrew V DeLong, Jared C Harris, Brittany S Larcart, Chandler B Massey, Chelsie D Northcutt, Somuayiro N Nwokike, Oscar A Otieno, Harsh M Patel, Mehulkumar P Patel, Pratik Pravin Patel, Eugene I Rowell, Brandon M Rush, Marc-Edwin G Saint-Louis, Amy M Vardeman, Felicia N Woods, Giso Abadi, Thomas J. Manning Computational Antibiotics Valdosta State University is located in South Georgia. Computational Antibiotics Index • Computational Details and Website Access (p. 8) • Acknowledgements (p. 9) • Dedications (p. 11) • Antibiotic Historical Introduction (p. 13) Introduction to Antibiotic groups • Penicillin’s (p. 21) • Carbapenems (p. 22) • Oxazolidines (p. 23) • Rifamycin (p. 24) • Lincosamides (p. 25) • Quinolones (p. 26) • Polypeptides antibiotics (p. 27) • Glycopeptide Antibiotics (p. 28) • Sulfonamides (p. 29) • Lipoglycopeptides (p. 30) • First Generation Cephalosporins (p. 31) • Cephalosporin Third Generation (p. 32) • Fourth-Generation Cephalosporins (p. 33) • Fifth Generation Cephalosporin’s (p. 34) • Tetracycline antibiotics (p. 35) Computational Antibiotics Antibiotics Covered (in alphabetical order) Amikacin (p. 36) Cefempidone (p. 98) Ceftizoxime (p. 159) Amoxicillin (p. 38) Cefepime (p. 100) Ceftobiprole (p. 161) Ampicillin (p. 40) Cefetamet (p. 102) Ceftoxide (p. 163) Arsphenamine (p. 42) Cefetrizole (p. 104) Ceftriaxone (p. 165) Azithromycin (p.44) Cefivitril (p. 106) Cefuracetime (p. 167) Aziocillin (p. 46) Cefixime (p. 108) Cefuroxime (p. 169) Aztreonam (p.48) Cefmatilen ( p. 110) Cefuzonam (p. 171) Bacampicillin (p. 50) Cefmetazole (p. 112) Cefalexin (p. 173) Bacitracin (p. 52) Cefodizime (p. 114) Chloramphenicol (p.175) Balofloxacin (p. 54) Cefonicid (p. 116) Cilastatin (p. 177) Carbenicillin (p. 56) Cefoperazone (p. 118) Ciprofloxacin (p. 179) Cefacetrile (p. 58) Cefoselis (p. 120) Clarithromycin (p. 181) Cefaclor (p.
    [Show full text]
  • Antibiotic Use for Sepsis in Neonates and Children: 2016 Evidence Update
    Antibiotic Use for Sepsis in Neonates and Children: 2016 Evidence Update Aline Fuchsa, Julia Bielickia,b, Shrey Mathurb, Mike Sharlandb, Johannes N. Van Den Ankera,c a Paediatric Pharmacology and Pharmacometrics, University Children's Hospital Basel, Basel, Switzerland b Paediatric Infectious Disease Research Group, Institute for Infection and Immunity, St George's University of London, London, United Kingdom c Division of Clinical Pharmacology, Children’s National Health System, Washington, DC, USA WHO-Reviews 1 TABLE OF CONTENTS 1. INTRODUCTION ............................................................................................................................... 3 1.1. Aims ......................................................................................................................................... 3 1.2. Background ............................................................................................................................. 3 1.2.1. Definition and diagnosis ................................................................................................. 3 Neonatal Sepsis ............................................................................................................................... 3 Paediatric Sepsis ............................................................................................................................. 4 Community versus hospital acquired sepsis .................................................................................. 5 1.2.2. Microbiology ..................................................................................................................
    [Show full text]
  • Antibiotic Dosing for Children: Draft Expert Recommendations for the 2017 Essential Medicines List for Children (Emlc)
    Antibiotic Dosing for Children: Draft expert Recommendations for the 2017 Essential Medicines List for Children (EMLc) Purpose and Scope of Recommendations Expert recommendations for antibiotic dosing in the EMLc have been developed to address the lack of harmony in currently available international formularies. In many instances, recommendations are historical practise-based and not strongly evidence-based. Limited evidence is available from studies of effectiveness and safety as well as all age pharmacokinetics for children. National preferences for weight-based (US), age-banded (UK) and weight-banded (WHO) dosing strategies have resulted in quite widely varying recommendations. The rationale of this dosing guidance has been to provide simple recommendations which are feasible in the LMIC context. Dosing guidance has been given as a single total daily dose (mg/kg/day) with options for acceptable frequency of dosing which can be adapted to local context. A maximum upper dose has been provided, largely based on available adult dosing. These recommendations have been developed for children ages 2 months to 12 years. In general, the aim was to produce a simple dosing guidance that covered all clinical infection syndromes, except severe infections such as meningitis, where significantly higher doses are recommended. Dosing recommendations have not been adjusted for children with renal or liver impairment. The recommendations have not accounted for global variation in rates of antimicrobial resistance. Using a single dose in this overall guidance does not reflect the range of doses that are actually required to translate the guidance into practical weight/age based formulations for children. Methods For the development of these recommendations, the expert group comprised paediatricians, paediatric clinical pharmacologists and pharmacists based in the UK and Europe.
    [Show full text]